Pharmaceuticals

Industry Trends Show Antiparasitic Drugs Market Set to Expand at 12.7% CAGR Until 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Much Is the Global Antiparasitic Drugs Market Valued at Present and by 2029?#_x000D_

The market for monoclonal antibodies (MAbs) has experienced rapid expansion in the recent past. The market is projected to increase from $231.42 billion in 2024 to $256.03 billion in 2025, recording a compound annual growth rate (CAGR) of 10.6%. The significant growth during the historic period is due to factors like the rise in chronic diseases, enhanced investment in research and development, increased understanding of MAbs, and the aging population._x000D_

_x000D_

The market size of monoclonal antibodies (MAbs) is projected to experience fast-paced expansion in the coming years. The anticipated growth puts the value at “$413.13 billion in 2029, with a compound annual growth rate (CAGR) of 12.7%.” Factors contributing to this growth over the forecast period include the broadening of therapeutic indications, the rise of personalized medicine and biosimilars, increased pandemic readiness, and investment in biopharmaceuticals. Key trends in the forecast period are expected to be advancements in immunotherapy, increased usage of subcutaneous administration and next-generation antibodies, digital health integration, and biotechnological progress._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp_x000D_

_x000D_

#What Drivers Are Influencing Growth In The Antiparasitic Drugs Market?_x000D_

The surge in cases of diseases spread by vectors is anticipated to fuel the antiparasitic drugs market’s expansion. Diseases transmitted by vectors, such as mosquitoes, ticks, and flies, refer to infectious illnesses passed on to humans or other animals via the biting arthropods, the primary vectors. Illnesses like malaria, dengue, and yellow fever qualify as examples of vector-borne diseases. Antiparasitic medications play a vital part in curbing the spread of such diseases by targeting and eradicating the causing parasites. Several antiparasitic medications like chloroquine, doxycycline, and atovaquone-proguanil are frequently utilized for treating malaria. For instance, data from the Centers for Disease Control and Prevention, a Government agency from the United States, shows that from January to June 2024, dengue cases reported across the Americas exceeded 9.7 million, about two-fold increase from the 4.6 million cases recorded in 2023. Within the United States, Puerto Rico registered 1,498 dengue cases and 745 cases were detected among U.S. travelers returning from infected regions. Hence, the rising prevalence of vector-borne diseases instigates the growth of the antiparasitic drugs market._x000D_

_x000D_

The monoclonal antibodies (mas) market covered in this report is segmented – _x000D_

_x000D_

1) By Source: Murine, Chimeric, Humanized, Human _x000D_

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications _x000D_

3) By End Users: Hospitals, Private Clinics, Research Institute _x000D_

_x000D_

Subsegments:_x000D_

1) By Murine: Fully Murine MAbs, Murine-Derived MAbs_x000D_

2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions_x000D_

3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs_x000D_

4) By Human: Fully Human MAbs, Engineered Human MAbs_x000D_

_x000D_

#What Long-Term Trends Are Likely To Affect The Antiparasitic Drugs Market?#_x000D_

The industry of monoclonal antibodies has observed a variety of strategic activities recently. Majors players in the market are tactically taking over start-ups and medium-sized firms to expand their offerings. Through strategic collaborations, acquisitions, and partnership deals, the vendors manage to grow their current product line and their geographical presence. For instance, in March 2022, a collaboration was announced by Sanofi S.A., a pharmaceutical and healthcare company based in France and Seagen Inc., an American pharmaceutical company that specializes in innovating and selling unique monoclonal antibody-based cancer treatments. According to the agreement, both companies will utilize their unique monoclonal antibody and antibody-drug conjugate technologies to create, refine, and promote antibody-drug conjugates for a maximum of three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based pharmaceutical research company, has revealed a collaboration with MabGenesis, Inc., a Japanese biopharmaceutical company focused on the creation of therapeutic monoclonal antibody treatments for human diseases. The collaboration resulted in Boehringer Ingelheim and MabGenesis discovering and creating novel therapeutic monoclonal antibodies to treat various diseases, and implementing strategic R&D strategies. Companies in the sector are progressively adjusting their portfolios and seeking out profitable inorganic growth opportunities. Moreover, due to robust corporate balance sheets, liquid debt markets, and consistent favourable global interest rates also contribute to an increased interest in M&As._x000D_

_x000D_

#Which Companies Play A Key Role In The Development Of The Antiparasitic Drugs Market?#_x000D_

Major companies operating in the monoclonal antibodies (MAbs) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report_x000D_

_x000D_

#What Are The Key Regional Developments Shaping The Antiparasitic Drugs Market?#_x000D_

North America was the largest region in the monoclonal antibodies (MAbS) market in 2024. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2554&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_